Acura Pharmaceuticals : Termination of Material Agreement :

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D. C. 20549



FORM 8-K


CURRENT REPORT


Pursuant to...
-Today at 11:24 am- MarketScreener

Related Keywords

Washington , United States , New York , Illinois , Petera Clemens , , Commission File Number , Abuse Deterrent Pharma , Exchange Commission , Securities Exchange , Name Of Each Exchange On Which , Pfizer Inc , Zyla Life Sciences , Development Inc , Limitx Technology , Egalet Corporation Zyla , N North Court , Growth Company , Pharmaceuticals Inc , Acura Pharmaceuticals Inc , Pfizer , King Pharmaceuticals Research , Exact Name , Each Exchange , Securities Act , Exchange Act , Securities Exchange Act , Emerging Growth Company , Material Definitive , Egalet Corporation , License Agreement , Acura Pharmaceuticals , Effective Date , Drug Application , Drug Administration , Par Pharmaceuticals , Current Report , Private Securities Litigation Reform Act , Markets ,